If you're looking for the best biotech stocks on the market, you've come to the right place.
Our biotech specialists aren't...
Pharmaceutical stocks can plummet for myriad reasons: loss of funding, lawsuits, poor clinical trials.
It's a risky sector to get...
Pharmaceutical stocks soar when their companies receive FDA approval. The key to investing in the pharmaceutical sector is research: you've got...
Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures...
Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news....
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second...
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if...
Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our...
The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as ...
When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion...
Market volatility has suddenly created some great opportunities, including those in the biotech sector.
Supporting the inevitable ...
When you're evaluating a biotech, or even a full-fledged pharmaceutical company, you'll want to look at its product pipeline, upcoming catalysts,...
Anyone who's very familiar with the bioscience/pharmaceutical sector will tell you investing in experimental drugs can be an object lesson in...
What a year so far for biotech stock profits...
Another consolidation in the active biotech sector came Tuesday when Cadence ...
This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.
The "patent cliff" refers...
IPO Calendar 2014: This year is forecast to be a record year for initial public offerings (IPOs).
Over the...
While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for...
While the Dow Jones Industrial Average fell 326...
Editor's Note: Today, we'd like to welcome Ernie Tremblay to Money Morning. He's been providing his bioscience...
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq:
